QSAM | Jotup

QSAM ANNOUNCES REVERSE STOCK SPLIT RATIO AHEAD OF MERGER

Retrieved on:

화요일, 4월 16, 2024

Agreement, TLX, OTCQB, ASX, Plan, Reverse stock split, Telix, Common stock, Information, QSAM, Security (finance)

Austin, TX, April 16, 2024 (GLOBE NEWSWIRE) -- QSAM Biosciences, Inc. (OTCQB: QSAM) (“QSAM” or the “Company”) previously announced that it will effectuate a reverse stock split of the issued and outstanding shares of QSAM’s common stock, par value $0.0001 per share (“Common Stock”), at a ratio in the range of 1:1000 to 1:2000, prior to the closing of the merger between the Company and Telix Pharmaceuticals Limited (ASX: TLX) (“Telix”) pursuant to which Telix will acquire QSAM (the “Merger”).

Key Points:

Austin, TX, April 16, 2024 (GLOBE NEWSWIRE) -- QSAM Biosciences, Inc. (OTCQB: QSAM) (“QSAM” or the “Company”) previously announced that it will effectuate a reverse stock split of the issued and outstanding shares of QSAM’s common stock, par value $0.0001 per share (“Common Stock”), at a ratio in the range of 1:1000 to 1:2000, prior to the closing of the merger between the Company and Telix Pharmaceuticals Limited (ASX: TLX) (“Telix”) pursuant to which Telix will acquire QSAM (the “Merger”).
On April 15, 2024, the Board of Directors of QSAM unanimously approved that the reverse stock split ratio be 1-for-2,000 such that once the reverse stock split goes into effect, every holder of Common Stock of the Company shall receive one share of Common Stock for every 2,000 shares of Common Stock held (the “Reverse Stock Split”).
On February 7, 2024, a majority of the voting shareholders of QSAM approved the reverse stock split and granted the Board the discretion to adopt the ratio prior to the closing of the Merger, which ratio the Board has adopted and is announcing today.
QSAM shareholders are encouraged to review the Information Statement for further information about the Merger and the Reverse Stock Split, which can be found on the SEC Edgar database: QSAM Definitive Information Statement .

Telix Signs Agreement to Acquire QSAM Biosciences and Its Bone Cancer Targeting Platform

Retrieved on:

수요일, 2월 7, 2024

MELBOURNE, Australia, Feb. 08, 2024 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces it has entered into an agreement to acquire QSAM Biosciences, Inc. (U.S. OTC: QSAM) and its lead investigational drug Samarium-153-DOTMP (153Sm-DOTMP).

Key Points:

MELBOURNE, Australia, Feb. 08, 2024 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces it has entered into an agreement to acquire QSAM Biosciences, Inc. (U.S. OTC: QSAM) and its lead investigational drug Samarium-153-DOTMP (153Sm-DOTMP).
QSAM is a United States (U.S.) based company developing therapeutic radiopharmaceuticals for primary and metastatic bone cancer.
Telix believes that 153Sm-DOTMP may benefit patients with metastatic lung and breast cancer, where many patients develop brain and bone metastases, and disease management often focusses on quality-of-life palliative care.
Telix will issue ordinary shares to the stockholders of QSAM at closing within its Listing Rule 7.1 placement capacity as consideration for the acquisition.

QSAM Biosciences Signs Definitive Agreement to be Acquired by Telix Pharmaceuticals

Retrieved on:

수요일, 2월 7, 2024

Regulation D, OTCQB, TLX, Patient, QSAM, Agreement, Acquisition, Metastasis, Samarium, Information, Radiopharmaceutical, ASX, Security (finance)

Austin, TX, Feb. 07, 2024 (GLOBE NEWSWIRE) -- QSAM Biosciences Inc. (OTCQB: QSAM) (“QSAM or the “Company”) has signed a definitive Agreement and Plan of Merger (the “Agreement”) providing for the acquisition of the Company by Telix Pharmaceuticals Limited (ASX: TLX) (“Telix”).

Key Points:

Austin, TX, Feb. 07, 2024 (GLOBE NEWSWIRE) -- QSAM Biosciences Inc. (OTCQB: QSAM) (“QSAM or the “Company”) has signed a definitive Agreement and Plan of Merger (the “Agreement”) providing for the acquisition of the Company by Telix Pharmaceuticals Limited (ASX: TLX) (“Telix”).
Prior to closing the merger, QSAM will effect a reverse stock split of its common stock in a ratio between 1:1000 and 1:2000.
Each whole share of QSAM common stock outstanding after the reverse split will receive Telix Shares.
All QSAM stockholders will receive one CVR for each QSAM common share held prior to the reverse split.

QSAM Biosciences Signs Term Sheet to be Acquired by Telix Pharmaceuticals; Receives $2 Million Pre-Closing Collaboration and Option Fee

Retrieved on:

화요일, 11월 14, 2023

Acquisition, OTCQB, TLX, QSAM, FDA, Nuclear pharmacy, ASX, Orphan drug, Contingent value rights, Term sheet, Commercial property, Telix

Upon signing of the Term Sheet, Telix has agreed to pay the Company a US$2 million Pre-Closing Collaboration and Option Fee (the “Collaboration Fee”) to advance the Company’s development efforts based on mutually agreed goals and to provide sixty days of exclusivity pending completion of diligence and execution of a definitive acquisition agreement.

Key Points:

Upon signing of the Term Sheet, Telix has agreed to pay the Company a US$2 million Pre-Closing Collaboration and Option Fee (the “Collaboration Fee”) to advance the Company’s development efforts based on mutually agreed goals and to provide sixty days of exclusivity pending completion of diligence and execution of a definitive acquisition agreement.
If the Acquisition does not close, the Collaboration Fee will be converted to Company common stock at a price of 6.70 per share.
Dr. C. Richard Piazza, QSAM’s Executive Chairman and co-Founder, stated, “We are thrilled to commence working with Telix by virtue of the Collaboration Fee to advance our technology and pursue a definitive agreement leading to the acquisition of QSAM by Telix.
With CycloSam® we plan to leverage Telix’s extensive experience and success in distributing short-life radiopharmaceuticals using a cold kit product from a nuclear pharmacy.

QSAM Biosciences Provides Update to Shareholders on Phase 1 Progress and Preliminary Clinical Data

Retrieved on:

수요일, 8월 16, 2023

In patients one and three, we saw no progression of tumor size at the four month follow-up.

Key Points:

In patients one and three, we saw no progression of tumor size at the four month follow-up.
We must remind our shareholders, however, that these results are very early and are not necessarily indicative of future results in our trials.
Further, this summary is not a formal read-out of data, but rather, a preliminary analysis of our Cohort 1 findings.
Ultimately, however, our primary mission is to help the hundreds of thousands of adults and children each year suffering from bone cancer.

QSAM Biosciences Adds the Nuclear Reactor at the University of Texas at Austin to its Radioisotope Production Supply Chain for its Bone Cancer Treatment Drug Candidate, CycloSam®

Retrieved on:

수요일, 6월 14, 2023

Tissue, Partnership, Radiation, Bone, University, Moses Austin, Cancer, OTCQB, Patient, Physician, QSAM, Nuclear, FDA, NETL, Void coefficient, Disease, University of Texas at Austin, Medical imaging, Uranium mining

QSAM is actively enrolling patients with metastatic bone cancer in a Phase I clinical trial across four clinical research centers in the United States.

Key Points:

QSAM is actively enrolling patients with metastatic bone cancer in a Phase I clinical trial across four clinical research centers in the United States.
“We have established a robust vetting and testing process to evaluate nuclear reactors to include in our supply chain.
NETL houses a 1.1-MW nuclear research reactor that is the newest research reactor in the US.
The addition of qualified nuclear reactors is expected to support QSAM’s clinical research and future commercial supply of Sm-153 if approved by the FDA.

QSAM Biosciences Expands its Study of CycloSam® in the Treatment of Bone Cancer; Opens Patient Enrollment at Key Chicago Center, Insight Hospital and Medical Center

Retrieved on:

화요일, 5월 23, 2023

Partnership, Bone, Cancer, Osteosarcoma, OTCQB, Breast, Prostate, MD, Patient, Sarcoma, Medical Center, RLS, Nuclear pharmacy, QSAM, Medical imaging, Pharmaceutical industry

QSAM’s study is a multiple center, open label, dose escalation clinical trial intended to determine the maximum tolerated dose of CycloSam® in patients, as well as assess early efficacy signals. Patients with bone cancer that has metastasized from the breast, lungs, prostate or other organs, as well as patients with cancer that has originated in the bone such as osteosarcoma and Ewing’s Sarcoma – diseases that mostly affect children and young adults -- may be eligible.

Key Points:

QSAM’s study is a multiple center, open label, dose escalation clinical trial intended to determine the maximum tolerated dose of CycloSam® in patients, as well as assess early efficacy signals.
Patients with bone cancer that has metastasized from the breast, lungs, prostate or other organs, as well as patients with cancer that has originated in the bone such as osteosarcoma and Ewing’s Sarcoma – diseases that mostly affect children and young adults -- may be eligible.
"We are pleased to be working with the excellent team at Insight Hospital and Medical Center to continue the expansion of our drug development program for CycloSam® in the large population center of Chicago,” stated Douglas R. Baum, CEO and co-founder of QSAM.
“Therapeutic radiopharmaceuticals like CycloSam® represent a novel and potentially important treatment option for patients suffering from this debilitating and deadly disease.”

QSAM Biosciences and RLS Announce Clinical and Commercial Supply Agreement for Promising Clinical-Stage Metastatic and Primary Bone Cancer Treatment, CycloSam®

Retrieved on:

화요일, 5월 16, 2023

Tissue, Bone Cancer Research Trust, Radiation, Bone, Half-life, OTCQB, Toxicity, Pharmacy, CDMO, Clinical trial, Patient, RLS, QSAM, FDA, Medical imaging, Pharmaceutical industry

Austin, TX and Lake Zurich, IL, May 16, 2023 (GLOBE NEWSWIRE) -- QSAM Biosciences, Inc. (OTCQB: QSAM), a clinical stage biotechnology company developing next-generation therapeutic radiopharmaceuticals, and RLS (USA) Inc., the third-largest nuclear medicine pharmacy network in the U.S., announced today a commercial supply and clinical dose preparation agreement for the therapeutic radiopharmaceutical drug candidate CycloSam® (Samarium-153 DOTMP), a promising clinical-stage treatment for metastatic and primary bone cancer in adults and children.

Key Points:

(OTCQB: QSAM), a clinical stage biotechnology company developing next-generation therapeutic radiopharmaceuticals, and RLS (USA) Inc. , the third-largest nuclear medicine pharmacy network in the U.S., announced today a commercial supply and clinical dose preparation agreement for the therapeutic radiopharmaceutical drug candidate CycloSam® (Samarium-153 DOTMP), a promising clinical-stage treatment for metastatic and primary bone cancer in adults and children.
QSAM is actively enrolling patients with metastatic bone cancer in a Phase I clinical trial for CycloSam® across three clinical sites in the United States with additional sites planned.
The RLS agreement is expected to support QSAM’s clinical research and potential future commercial use of CycloSam®.
Stephen Belcher, CEO of RLS, added, “RLS is proud to partner with the talented management team at QSAM in support of these important clinical trials.

QSAM Biosciences Receives Second Key Patent in Europe for its Clinical Stage Radiopharmaceutical Drug Candidate, CycloSam®

Retrieved on:

수요일, 4월 26, 2023

Bone, European Patent Office, Cancer, OTCQB, Breast, Prostate, IP, Lung, EPO, Patent, Patient, European Patent Convention, Kidney, QSAM, FDA, Pharmaceutical industry, EU

This new patent in Europe covers the “high purity therapeutic bone agents” technology exclusively licensed to QSAM on a worldwide basis and relates to the novel manner in which the Samarium-153 is produced for use in CycloSam®.

Key Points:

This new patent in Europe covers the “high purity therapeutic bone agents” technology exclusively licensed to QSAM on a worldwide basis and relates to the novel manner in which the Samarium-153 is produced for use in CycloSam®.
These types of metastasized bone cancer are the subject of QSAM’s current FDA-cleared Phase 1 clinical trial which is underway and actively enrolling and dosing patients.
“This allowance by the EPO marks our second patent in Europe, and we expect to register the patent in multiple individual countries in the EU over the following few weeks, thereby expanding our already established and robust patent estate.
More so, this additional IP protection broadens our potential commercial market for what we believe may eventually be a breakthrough therapy for both primary and secondary forms of bone cancer,” added Mr. Baum.

QSAM Biosciences Opens Enrollment of the Second Cohort of Patients in its Phase 1 Study of CycloSam® Targeting Metastatic Bone Cancer

Retrieved on:

수요일, 4월 5, 2023

Bone, Cohort, Clinical trial, Osteosarcoma, OTCQB, Woman, Breast, Prostate, Lung, Cancer, Patient, Growth, American Cancer Society, QSAM, Safety, Breast cancer, Pharmaceutical industry, Medical imaging

“We have met all criteria to continue patient enrollment at a higher dose level in the next group of patients,” stated Douglas R. Baum, CEO.

Key Points:

“We have met all criteria to continue patient enrollment at a higher dose level in the next group of patients,” stated Douglas R. Baum, CEO.
The total dosage of the active radioisotope Samarium-153 to be received by participants in the second cohort is 50% higher than the total dose received by participants in the first cohort.
QSAM is dedicated to developing its Cyclosam® product for this important patient population, and patients with any of these bone cancer types are eligible for this clinical trial.
Osteosarcoma, while still a rare pediatric disease, is the most common form of bone cancer in children and young adults (ages 15-39) with primary high-grade bone malignancy; and Ewing’s Sarcoma bone cancer is the second most common form of bone cancer in children.